ABUS

Arbutus Biopharma

Fundamental data last updated:April 13, 2026

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

05/13/26

Business Summary

Arbutus Biopharma operates as a clinical-stage biotechnology company focused on developing therapeutics, likely targeting high-value viral or liver-related diseases. The company generates no meaningful earnings today, instead reinvesting capital into research, intellectual property development, and clinical trials. Its moat is intellectual property—patents, proprietary formulations, and specialized scientific expertise that, if validated, can command pricing power in niche therapeutic markets. Cash generation is binary and milestone-driven: successful trials unlock partnerships, licensing deals, or commercialization pathways, while failure erases invested capital. This is a high-risk, IP-dependent model where scientific differentiation—not current cash flow—defines competitive advantage.

VALUATION

P/E

-

Market Cap ($M USD)

$811

Forward P/E

-

PEG

-

PRICE TO SALES

56.5

PRICE TO BOOK

10.6

EV / EBITDA

-21.8

5-Year Average P/E

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$0.17

Next Year EPS Growth Estimate

-

Next Year Revenue Growth Estimate

-

Return on Equity (ROE)

-43.70%

Operating Margin

-192.10%

Debt-to-Equity

0

Piotroski F-Score

4

Altman Z-Score

6.9

Return on Invested Capital (ROIC)

-42.60%%

Current Ratio

15.7

Quick Ratio

Gainseekers Quantitative Analysis

Summary

Arbutus Biopharma is a pure speculation vehicle masquerading as a $811M enterprise. With no P/E, no Forward P/E, and no PEG, the market has no earnings anchor to underwrite valuation, and a Price/Sales of 56.5 alongside a Price/Book of 10.6 signals investors are paying extreme premiums for an unprofitable platform. EPS sits at -21.8 with operating margins at -43.70% and ROIC at -42.60%, confirming capital destruction rather than value creation. The only real pillar of safety is an Altman Z-Score of 6.9 and a massive Current Ratio of 15.7, which scream balance-sheet solvency despite the negative earnings profile. This is not mispricing based on fundamentals—it’s pricing optionality around future drug success while burning capital today.

AI Exposure / Tech Reliance

As a biotechnology company in Healthcare, Arbutus operates in an industry increasingly driven by AI-enabled drug discovery, genomics analytics, and precision medicine platforms. While no specific R&D metrics are provided, biotech firms structurally benefit from computational biology and data-driven trial optimization. The sector tailwind exists, but without revenue growth metrics or profitability, AI leverage remains theoretical rather than proven in the numbers.

The Bull Case

A GARP or deep-value investor could argue that the balance sheet is the hidden asset here. A Current Ratio of 15.7 combined with an Altman Z-Score of 6.9 indicates very low near-term bankruptcy risk, giving management runway to execute. The Piotroski F-Score of 4 is neutral—not strong, but not catastrophic—and suggests financial condition is mixed rather than collapsing. Despite deeply negative ROIC (-42.60%) and operating margins (-43.70%), biotech investors often underwrite pipeline optionality years before profitability materializes. If even one program converts into commercial revenue, today’s $811M market cap could look conservative relative to biotech payoff asymmetry.

The Bear Case

The red flags are glaring and structural. A Price/Sales of 56.5 with no earnings, no forward earnings, and no PEG ratio signals extreme valuation disconnected from current fundamentals. Debt/Equity at -192.10% reflects an unconventional capital structure likely driven by accumulated deficits, while EPS of -21.8 underscores severe losses. Operating Margin of -43.70% and ROIC of -42.60% confirm that every incremental dollar deployed is currently destroying value. With no dividend, no yield, and no visible growth metrics, investors are funding a cash-burning R&D engine with no demonstrated economic return.

Market Sentiment & Smart Money

Short Interest %

12.10%

Analyst Consensus

1.67

Average Analyst Price Target

$5.25

Institutional Ownership %

63.50%

1-Year Beta

1.18

Insider Buying % (6 Mo)

21.50%%

Distance to 52-Week High

81.40%%

Distance to 52-Week Low

141.20%%